NeuroQore, Inc., is set to commercialize a new patented monophasic repetitive transcranial magnetic stimulation (rTMS) system with a potentially improved remission rate. The first unit of the NeuroQore rTMS system was installed at the Royal Ottawa Mental Health Centre in July 2015 and successfully passed tolerability testing on healthy volunteers in a pilot project. The company is now in the midst of recruiting patients for the next round of testing. Preliminary clinical data is promising and has prompted installation of more units to recruit more patients faster.
Major depressive disorder affects approximately 4.7% world population annually and 1 in 3 do not recover with medications or therapy. For treatment-resistant depression (TRD), electroconvulsive therapy (ECT) is effective (60-70% remission), but hampered by the need for anesthesia, significant cognitive side effects, and high stigma. Less than 1% of TRD population receive ECT annually.
Repetitive transcranial magnetic stimulation (rTMS) is an emerging therapeutic brain stimulation technique that does not require anesthesia, has no cognitive side effects, and is widely accepted by patients. rTMS is currently administered by a technician or nurse in an outpatient clinical setting. The potency and efficacy of conventional biphasic rTMS (45-55% response, 30-35% remission) falls between medications and ECT, but rTMS offers the advantages of high tolerability and accessibility.
NeuroQore monophasic rTMS system with an improved remission rate has potential to be a disruptive innovation that results in improved health care worldwide. NeuroQore is looking to effectively integrate into existing health-care facilities and coordinated with ongoing treatments as a complement to medications and therapy.
San Francisco: 415 590 3003
Newport Beach: 949 397 1333
Ottawa: 613 264 7048
Thank you for visiting NeuroQore.com
Please take a moment to fill out this survey!